1 / 36

MAST Safety (Domain 2) Clinical Effectiveness (Domain 3)

MAST Safety (Domain 2) Clinical Effectiveness (Domain 3). Reinhard Prior, HIM, Berlin May 5, 2010. Basic principles of MAST. Strong consideration of the existing literature when implementing a new trial Use of validated, and generally accepted outcomes

britanni-oliver
Download Presentation

MAST Safety (Domain 2) Clinical Effectiveness (Domain 3)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MAST Safety (Domain 2) Clinical Effectiveness (Domain 3) Reinhard Prior, HIM, Berlin May 5, 2010

  2. Basic principles of MAST Strong consideration of the existing literature when implementing a new trial Use of validated, and generally accepted outcomes ‘Holistic approach’ considering several domains (not only clinical effectiveness)

  3. Effectiveness ”The ability to produce a desired result under real life conditions” “Pragmatic trial”

  4. Efficacy ”The ability to produce a desired result under strictly controlled conditions” “Explanatory trial”

  5. Which are the ‘desired results’ from a clinical point of view?

  6. Generic outcomes(Not disease-specific)

  7. All-cause mortality All-cause morbidity Generic Health related Qol instruments (SF-36/12, EQ-5D) Health care service utilisation

  8. Number of hospitalisations • Number of hospital bed days • Number of visits to emergency rooms • Number of visits by specialists • Number of visits by GPs • Number of visits by nurses

  9. Disease-specific outcomes(not disease-specific) Objective measurements Hb A1c, cholesterol FEV1 NYHA-class, LVEF Scores, Questionnaires, HRQol-questionnaires Depression scales

  10. Requirements for primary outcomes • Must be suitable to statistical analysis • Must be easy to collect • When a score, must be available and validated in all local languages

  11. What has already been done? Literature overview

  12. Paré et al. 50% of studies: non randomization, no control group 8 % of studies: non randomized with control group

  13. Paré et al Paré et al.

  14. Paré et al Paré et al.

  15. Paré et al

  16. Paré et al

  17. Paré et al

  18. How can Renewing Health do it better?

  19. Careful design considering the missing evidence and missing aspects (not just replication of previous research) Large scale MAST

  20. Patient / population ? Intervention ? Comparator ? Outcomes ?

  21. Levels of evidence: RCT with large sample size RCT with small sample size Prospective study with non randomized control group Retrospective study with non randomized control group Cohort study Case control study Descriptive studies Case reports

  22. Randomized controlled trial Quasi experimental methods (‘matched comparison’)

  23. MAST A basis to facilitate an integrated evaluation of those domains that have not been addressed or have been insufficiently adressed by previous research.

  24. Thank you!

More Related